{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:17:36Z","timestamp":1787761056406,"version":"build-2784847793"},"reference-count":41,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:italic toggle=\"yes\">Mycobacterium tuberculosis<\/jats:italic>\n                      is the leading cause of mortality worldwide due to a single bacterial pathogen. Of concern is the negative impact that the COVID-19 pandemic has had on the control of tuberculosis (TB) including drug-resistant forms of the disease. Antimicrobial resistance increases the likelihood of worsened outcomes in TB patients including treatment failure and death. Multidrug-resistant (MDR) strains, resistant to first-line drugs isoniazid and rifampin, and extensively drug-resistant (XDR) strains with further resistance to second-line drugs (SLD), threaten control programs designed to lower TB incidence and end the disease as a public health challenge by 2030, in accordance with UN Sustainable Development Goals. Tackling TB requires an understanding of the pathways through which drug resistance emerges. Here, the roles of acquired resistance mutation, and primary transmission, are examined with regard to XDR-TB. It is apparent that XDR-TB can emerge from MDR-TB through a small number of additional resistance mutations that occur in patients undergoing drug treatment. Rapid detection of resistance, to first-line drugs and SLD, at the initiation of and during treatment, and prompt adjustment of regimens are required to ensure treatment success in these patients. Primary transmission is predicted to make an increasing contribution to the XDR-TB caseload in the future. Much work is required to improve the implementation of the World Health Organization-recommended infection control practices and block onward transmission of XDR-TB patients to contacts including health-care workers. Finally, limiting background resistance to fluoroquinolones in pre-XDR strains of\n                      <jats:italic toggle=\"yes\">M. tuberculosis<\/jats:italic>\n                      will necessitate better antimicrobial stewardship in the broader use of this drug class.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijmy.ijmy_187_22","type":"journal-article","created":{"date-parts":[[2022,12,10]],"date-time":"2022-12-10T05:30:33Z","timestamp":1670650233000},"page":"343-348","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":15,"title":["Antibiotic Resistance Acquisition versus Primary Transmission in the Presentation of Extensively Drug-Resistant Tuberculosis"],"prefix":"10.4103","volume":"11","author":[{"given":"Ronan Francis","family":"O'Toole","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R4-1-20240902","doi-asserted-by":"crossref","first-page":"e178","DOI":"10.26633\/RPSP.2020.178","article-title":"Primary and acquired multidrug-resistant tuberculosis: Predictive factors for unfavorable treatment outcomes in Rio de Janeiro, 2000-2016","volume":"44","author":"Bhering","year":"2020","journal-title":"Rev Panam Salud Publica"},{"key":"R5-1-20240902","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1053\/jinf.2000.0711","article-title":"Comparison of fitness of two isolates of Mycobacterium tuberculosis, one of which had developed multi-drug resistance during the course of treatment","volume":"41","author":"Davies","year":"2000","journal-title":"J Infect"},{"key":"R6-1-20240902","doi-asserted-by":"crossref","first-page":"287","DOI":"10.4103\/ijmy.ijmy_97_19","article-title":"Competitive fitness of Mycobacterium tuberculosis in vitro","volume":"8","author":"Kodio","year":"2019","journal-title":"Int J Mycobacteriol"},{"key":"R7-1-20240902","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/ng.1038","article-title":"Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes","volume":"44","author":"Comas","year":"2011","journal-title":"Nat Genet"},{"key":"R8-1-20240902","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s12041-017-0805-8","article-title":"Fitness-compensatory mutations facilitate the spread of drug-resistant F15\/LAM4\/KZN and F28 Mycobacterium tuberculosis strains in KwaZulu-Natal, South Africa","volume":"96","author":"Naidoo","year":"2017","journal-title":"J Genet"},{"key":"R9-1-20240902","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1093\/infdis\/jiv347","article-title":"Fitness costs of drug resistance mutations in multidrug-resistant Mycobacterium tuberculosis: A household-based case-control study","volume":"213","author":"Salvatore","year":"2016","journal-title":"J Infect Dis"},{"key":"R10-1-20240902","first-page":"418","article-title":"Multidrug-resistant Tuberculosis treatment outcomes in relation to treatment and initial versus acquired second-line drug resistance","volume":"62","author":"Cegielski","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R15-1-20240902","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijmyco.2013.04.005","article-title":"Totally drug-resistant tuberculosis (TDR-TB): A debate on global health communities","volume":"2","author":"Velayati","year":"2013","journal-title":"Int J Mycobacteriol"},{"key":"R17-1-20240902","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/S0140-6736(06)69573-1","article-title":"Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa","volume":"368","author":"Gandhi","year":"2006","journal-title":"Lancet"},{"key":"R18-1-20240902","doi-asserted-by":"crossref","first-page":"e7778","DOI":"10.1371\/journal.pone.0007778","article-title":"Genome analysis of multi and extensively-drug-resistant tuberculosis from KwaZulu-Natal, South Africa","volume":"4","author":"Ioerger","year":"2009","journal-title":"PLoS One"},{"key":"R19-1-20240902","first-page":"99","article-title":"Genotypic diversity of extensively drug-resistant tuberculosis (XDR-TB) in South Africa","volume":"12","author":"Mlambo","year":"2008","journal-title":"Int J Tuberc Lung Dis"},{"key":"R20-1-20240902","doi-asserted-by":"crossref","first-page":"3650","DOI":"10.1128\/JCM.01414-15","article-title":"Molecular epidemiological interpretation of the epidemic of extensively drug-resistant tuberculosis in South Africa","volume":"53","author":"Streicher","year":"2015","journal-title":"J Clin Microbiol"},{"key":"R21-1-20240902","doi-asserted-by":"crossref","first-page":"110278","DOI":"10.1016\/j.ygeno.2022.110278","article-title":"Comparative genomic analyses of multi-drug resistant Mycobacterium tuberculosis from Nepal and other geographical locations","volume":"114","author":"Leong","year":"2022","journal-title":"Genomics"},{"key":"R23-1-20240902","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.ijmyco.2015.05.012","article-title":"Fluoroquinolones resistance in multidrug-resistant tuberculosis in Pakistan and suitability of guidelines recommended standardized regimen","volume":"4","author":"Ahmad","year":"2015","journal-title":"Int J Mycobacteriol"},{"key":"R25-1-20240902","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fmed.2019.00105","article-title":"Antimicrobial resistance in Nepal","volume":"6","author":"Acharya","year":"2019","journal-title":"Front Med (Lausanne"},{"key":"R26-1-20240902","doi-asserted-by":"crossref","first-page":"47","DOI":"10.3390\/tropicalmed6020047","article-title":"Antibiotic use in broiler poultry farms in Kathmandu Valley of Nepal: Which antibiotics and why?","volume":"6","author":"Koirala","year":"2021","journal-title":"Trop Med Infect Dis"},{"key":"R27-1-20240902","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1093\/cid\/ciu572","article-title":"Extensive drug resistance acquired during treatment of multidrug-resistant tuberculosis","volume":"59","author":"Cegielski","year":"2014","journal-title":"Clin Infect Dis"},{"key":"R28-1-20240902","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/jac\/dks371","article-title":"From multidrug-resistant to extensively drug-resistant tuberculosis in Lisbon, Portugal: The stepwise mode of resistance acquisition","volume":"68","author":"Perdig\u00e3o","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"R29-1-20240902","doi-asserted-by":"crossref","first-page":"e1001880","DOI":"10.1371\/journal.pmed.1001880","article-title":"Evolution of extensively drug-resistant tuberculosis over four decades: Whole genome sequencing and dating analysis of Mycobacterium tuberculosis isolates from Kwazulu-Natal","volume":"12","author":"Cohen","year":"2015","journal-title":"PLoS Med"},{"key":"R30-1-20240902","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1186\/s13059-014-0490-3","article-title":"Evolution of extensively drug-resistant Mycobacterium tuberculosis from a susceptible ancestor in a single patient","volume":"15","author":"Eldholm","year":"2014","journal-title":"Genome Biol"},{"key":"R31-1-20240902","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.bjid.2016.01.004","article-title":"Evaluation of resistance acquisition during tuberculosis treatment using whole genome sequencing","volume":"20","author":"Silva Feliciano","year":"2016","journal-title":"Braz J Infect Dis"},{"key":"R32-1-20240902","doi-asserted-by":"crossref","first-page":"e82551","DOI":"10.1371\/journal.pone.0082551","article-title":"Whole genome sequencing reveals complex evolution patterns of multidrug-resistant Mycobacterium tuberculosis Beijing strains in patients","volume":"8","author":"Merker","year":"2013","journal-title":"PLoS One"},{"key":"R33-1-20240902","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.3201\/eid2106.141907","article-title":"Risk factors for acquisition of drug resistance during multidrug-resistant tuberculosis treatment, Arkhangelsk Oblast, Russia, 2005-2010","volume":"21","author":"Smith","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"R34-1-20240902","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1093\/cid\/cis748","article-title":"Acquired resistance to second-line drugs among persons with tuberculosis in the United States","volume":"55","author":"Ershova","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R35-1-20240902","doi-asserted-by":"crossref","first-page":"e70919","DOI":"10.1371\/journal.pone.0070919","article-title":"Programmatically selected multidrug-resistant strains drive the emergence of extensively drug-resistant tuberculosis in South Africa","volume":"8","author":"M\u00fcller","year":"2013","journal-title":"PLoS One"},{"key":"R36-1-20240902","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1016\/j.cmi.2021.04.001","article-title":"Emergence of additional drug resistance during treatment of multidrug-resistant tuberculosis in China: A prospective cohort study","volume":"27","author":"Hu","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R37-1-20240902","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1056\/NEJMoa1604544","article-title":"Transmission of extensively drug-resistant tuberculosis in South Africa","volume":"376","author":"Shah","year":"2017","journal-title":"N Engl J Med"},{"key":"R38-1-20240902","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1128\/AAC.03504-14","article-title":"Evolution and transmission patterns of extensively drug-resistant tuberculosis in China","volume":"59","author":"Wang","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"R39-1-20240902","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.jinf.2016.04.037","article-title":"XDR-TB transmission in London: Case management and contact tracing investigation assisted by early whole genome sequencing","volume":"73","author":"Arnold","year":"2016","journal-title":"J Infect"},{"key":"R40-1-20240902","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.medmal.2015.12.008","article-title":"XDR-tuberculosis in France: Community transmission due to non-compliance with isolation precautions","volume":"46","author":"Lafeuille","year":"2016","journal-title":"Med Mal Infect"},{"key":"R41-1-20240902","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1128\/JCM.02116-16","article-title":"Whole-genome sequencing of Mycobacterium tuberculosis provides insight into the evolution and genetic composition of drug-resistant tuberculosis in Belarus","volume":"55","author":"Wollenberg","year":"2017","journal-title":"J Clin Microbiol"},{"key":"R42-1-20240902","doi-asserted-by":"crossref","first-page":"22","DOI":"10.5588\/ijtld.13.0109","article-title":"Health care workers' fears associated with working in multidrug and or extensively-resistant tuberculosis wards in South Africa","volume":"17","author":"Tudor","year":"2013","journal-title":"Int J Tuberc Lung Dis"},{"key":"R43-1-20240902","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1093\/cid\/ciw037","article-title":"Exposed, but not protected: More is needed to prevent drug-resistant tuberculosis in healthcare workers and students","volume":"62","author":"von Delft","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R44-1-20240902","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1473-3099(17)30247-5","article-title":"Estimating the future burden of multidrug-resistant and extensively drug-resistant tuberculosis in India, the Philippines, Russia, and South Africa: A mathematical modelling study","volume":"17","author":"Sharma","year":"2017","journal-title":"Lancet Infect Dis"},{"key":"R45-1-20240902","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.cmi.2016.10.008","article-title":"Clinical management of adults and children with multidrug-resistant and extensively drug-resistant tuberculosis","volume":"23","author":"Dheda","year":"2017","journal-title":"Clin Microbiol Infect"},{"key":"R47-1-20240902","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1183\/09031936.00079413","article-title":"Costs of tuberculosis disease in the European Union: A systematic analysis and cost calculation","volume":"43","author":"Diel","year":"2014","journal-title":"Eur Respir J"},{"key":"R49-1-20240902","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1080\/17476348.2016.1199278","article-title":"WHO strategies for the programmatic management of drug-resistant tuberculosis","volume":"10","author":"Matteelli","year":"2016","journal-title":"Expert Rev Respir Med"},{"key":"R51-1-20240902","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1183\/09031936.00029311","article-title":"TB and M\/XDR-TB infection control in European TB reference centres: The Achilles' heel?","volume":"38","author":"Sotgiu","year":"2011","journal-title":"Eur Respir J"},{"key":"R52-1-20240902","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.5114\/pjr.2020.93123","article-title":"Computerised tomography scan in multi-drug-resistant versus extensively drug-resistant tuberculosis","volume":"85","author":"Mehrian","year":"2020","journal-title":"Pol J Radiol"},{"key":"R53-1-20240902","first-page":"191","article-title":"The role of drug susceptibility testing in M\/XDR-TB","volume":"2","author":"Hoffner","year":"2013","journal-title":"Too little and too late \u2013 Are we doing the right things? Int J Mycobacteriol"},{"key":"R54-1-20240902","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.rmed.2017.09.007","article-title":"Infection control, genetic assessment of drug resistance and drug susceptibility testing in the current management of multidrug\/extensively-resistant tuberculosis (M\/XDR-TB) in Europe: A Tuberculosis Network European Trialsgroup (TBNET) study","volume":"132","author":"Bothamley","year":"2017","journal-title":"Respir Med"}],"container-title":["The International Journal of Mycobacteriology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_187_22","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:17:57Z","timestamp":1787757477000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijmy.ijmy_187_22"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.4103\/ijmy.ijmy_187_22","relation":{},"ISSN":["2212-5531"],"issn-type":[{"value":"2212-5531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]}}}